1
|
Hong S, Yuan Q, Xia H, Dou Y, Sun T, Xie T, Zhang Z, He W, Dong C, Lu J, Guo L, Ni L. Establishment of an Ex Vivo Tissue Culture Model for Evaluation of Antitumor Efficacy in Clear Cell Renal Cell Carcinoma. Front Oncol 2022; 12:851191. [PMID: 35463322 PMCID: PMC9019348 DOI: 10.3389/fonc.2022.851191] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2022] [Accepted: 03/03/2022] [Indexed: 12/03/2022] Open
Abstract
There are many potential immunotherapeutic targets for cancer immunotherapy, which should be assessed for efficacy before they enter clinical trials. Here we established an ex vivo cultured patient-derived tumor tissue model to evaluate antitumor effectiveness of one VISTA inhibitor, given that our previous study showed that VISTA was selectively highly expressed in human clear cell renal cell carcinoma (ccRCC) tumors. We observed that all the tested patients responded to the anti-VISTA monoclonal antibody as manifested by TNF-α production, but only a small fraction were responders to the anti-PD-1 antibody. Co-blockade of VISTA and PD-1 resulted in a synergistic effect in 20% of RCC patients. Taken together, these findings indicate that this ex vivo tumor slice culture model represents a viable tool to evaluate antitumor efficacies for the inhibitors of immune checkpoints and further supports that VISTA could serve as a promising target for immunotherapy in ccRCC.
Collapse
Affiliation(s)
- Shanjuan Hong
- Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China
| | - Qing Yuan
- Department of Urology, The Third Medical Center of Chinese Peoples Liberation Army (PLA) General Hospital, Beijing, China
| | - Haizhui Xia
- Department of Urology, Peking University Third Hospital, Beijing, China
| | - Yuan Dou
- R&D Center, Suzhou Kanova Biopharmaceutical Co., Ltd., Suzhou, China
| | - Tiantian Sun
- R&D Center, Suzhou Kanova Biopharmaceutical Co., Ltd., Suzhou, China
| | - Tian Xie
- Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China
| | - Zhiyin Zhang
- Department of Urology, Peking University Third Hospital, Beijing, China
| | - Wei He
- Department of Urology, Peking University Third Hospital, Beijing, China
| | - Chen Dong
- Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China.,Center for Human Disease Immuno-Monitoring, Beijing Friendship Hospital, Beijing, China
| | - Jian Lu
- Department of Urology, Peking University Third Hospital, Beijing, China
| | - Li Guo
- R&D Center, Suzhou Kanova Biopharmaceutical Co., Ltd., Suzhou, China
| | - Ling Ni
- Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China.,Center for Human Disease Immuno-Monitoring, Beijing Friendship Hospital, Beijing, China
| |
Collapse
|